Search

Your search keyword '"Heera J"' showing total 88 results

Search Constraints

Start Over You searched for: Author "Heera J" Remove constraint Author: "Heera J"
88 results on '"Heera J"'

Search Results

1. A Game-Theoretic Model of Voluntary Yellow Fever Vaccination to Prevent Urban Outbreaks

4. Dynamic Nondestructive Detection Models of Apple Quality in Critical Harvest Period Based on Near-Infrared Spectroscopy and Intelligent Algorithms

6. Spoilage Monitoring and Early Warning for Apples in Storage Using Gas Sensors and Chemometrics

7. Determination of Dicofol in Tea Using Surface-Enhanced Raman Spectroscopy Coupled Chemometrics

8. Development of a Sensitive SERS Method for Label-Free Detection of Hexavalent Chromium in Tea Using Carbimazole Redox Reaction

9. Population and ultra‐deep sequencing for tropism determination are correlated with Trofile ES: genotypic re‐analysis of the A4001078 maraviroc study

10. Short‐term variation of HIV tropism readouts in the absence of CCR5 antagonists

11. Maraviroc (MVC) increases CD4+ and CD8+ cells: long‐term data from the MVC clinical development program

12. TUPDB0204: Very early initiation of combination antiviral therapy results in normal levels of markers of immune activation

13. Efficacy and safety of Maraviroc vs. Efavirenz in treatment-naive patients with HIV-1: 5-year findings

16. Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients

18. Improvement of bioavailability for resveratrol through encapsulation in zein using electrospraying technique

20. O123. Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists.

21. O125. Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients.

22. Towards Better Evaluation of Pneumococcal Vaccines.

23. Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial

24. Acute separate and combined effects of cannabinoid and nicotinic receptor agonists on MMN-indexed auditory deviance detection in healthy humans.

25. First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.

26. No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.

27. Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.

28. Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.

29. Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.

31. Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.

33. Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.

34. The maraviroc expanded access program - safety and efficacy data from an open-label study.

35. First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN.

37. Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial.

38. The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers.

39. The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers.

40. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.

41. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.

42. Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.

43. Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.

44. Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original trofile assay in non-B subtypes.

45. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.

46. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.

47. Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078.

48. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.

49. Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.

50. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.

Catalog

Books, media, physical & digital resources